Related Experiment Video
Updated: Mar 8, 2026
Transgenic Rodent Assay for Quantifying Male Germ Cell Mutant Frequency
Published on: August 6, 2014
The epigenetics of testicular germ cell tumors: looking for novel disease biomarkers
Ana Laura Costa1,2, João Lobo1,3,2, Carmen Jerónimo1,2
1Cancer Biology & Epigenetics Group, Research Center of Portuguese Oncology Institute of Porto (CI-IPOP), Porto, Portugal.
Abstract:
Testicular germ cell tumors (TGCT) are a group of heterogeneous, biologically diverse and clinically challenging neoplasms. Despite the relatively low incidence and mortality rates, a subgroup of patients with disseminated disease relapse after conventional therapy and have a dismal prognosis. Moreover, TGCT afflict mostly young men and have therapeutic peculiarities, with some patients showing resistance to cisplatin-based treatments and others being troubled by irreversible side effects, such as infertility. Most TGCT share a common tumorigenic pathway and are cytogenetically similar, making room for Epigenetics to explain its heterogeneity at pathological and clinical level. In this review, we summarize the foremost epigenetic alterations among TGCT focusing on their clinical potential as diagnostic, prognostic and predictive biomarkers.
Insights
Testicular germ cell tumors (TGCT) are diverse cancers in young men. Epigenetic alterations may explain TGCT heterogeneity and offer potential as biomarkers for diagnosis and prognosis.
Area of Science:
- Oncology
- Genetics
- Epigenetics
Background:
- Testicular germ cell tumors (TGCT) are heterogeneous neoplasms affecting young men.
- A subset of patients with disseminated TGCT experience relapse post-treatment, facing a poor prognosis.
- Therapeutic challenges include cisplatin resistance and irreversible side effects like infertility.
Purpose of the Study:
- To review epigenetic alterations in TGCT.
- To explore the clinical potential of epigenetic modifications as diagnostic, prognostic, and predictive biomarkers.
Main Methods:
- Literature review of epigenetic alterations in TGCT.
- Analysis of studies focusing on the clinical utility of epigenetic biomarkers.
Main Results:
- Epigenetic mechanisms contribute to the pathological and clinical heterogeneity of TGCT.
- Specific epigenetic alterations show promise as biomarkers for TGCT management.
Conclusions:
- Epigenetics offers insights into TGCT diversity and therapeutic resistance.
- Epigenetic biomarkers hold potential for improving TGCT diagnosis, prognosis, and treatment prediction.
More Related Videos
06:32Evaluation of Biomarkers in Glioma by Immunohistochemistry on Paraffin-Embedded 3D Glioma Neurosphere Cultures
Published on: January 9, 2019
07:41Performing Data Mining And Integrative Analysis Of Biomarker in Breast Cancer Using Multiple Publicly Accessible Databases
Published on: May 17, 2019